Skip to main content

Articles

Conference Correspondent, ASH 2016 - Multiple Myeloma
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Read More
Page 102 of 245
Results 1011 - 1020 of 2441